1 / 24

The PPAR Journey: What Can We Expect in the Future?

The PPAR Journey: What Can We Expect in the Future?. Targets of Glucose-Lowering Drugs. PPAR- a and PPAR- g Agonists: Target Systems. Effects of Fibrates on Cardiovascular Events: A Systematic Review and Meta-Analysis . CV Events With PPAR- g Agonists.

raeanne
Download Presentation

The PPAR Journey: What Can We Expect in the Future?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The PPAR Journey: What Can We Expect in the Future?

  2. Targets of Glucose-Lowering Drugs

  3. PPAR-a and PPAR-g Agonists: Target Systems

  4. Effects of Fibrates on Cardiovascular Events: A Systematic Review and Meta-Analysis

  5. CV Events With PPAR-g Agonists

  6. Expected Targets for Dual PPAR-a/g Agonists

  7. Dual PPAR a/g Agonists

  8. GALLANT 8: Effect of Tesaglitazar on Top of Metformin vs Metformin Alone on HbA1c

  9. GLAD: Effect of Tesaglitazar vs Pioglitazone on Lipid Measures

  10. Tesaglitazar: Effect on Serum Creatinine and Glomerular Filtration

  11. Dual a/g PPAR Agonist: Effect of Muraglitazar on Metabolic Parameters

  12. Effect of Muraglitazar on CV Outcomes

  13. SYNCHRONY: Effect of Aleglitazar on Cardiometabolic Parameters in T2D

  14. SYNCHRONY: Cardiovascular Safety

  15. SYNCHRONY: Effect of Aleglitazar on Markers of Renal Function

  16. SESTA R: Impact of Supratherapeutic Doses of Aleglitazar on Renal Function in T2D

  17. ALENEPHRO: Objective and Study Design

  18. Summary: PPAR Therapy

  19. Abbreviations

  20. Abbreviations (cont)

  21. References

  22. References (cont)

  23. References (cont)

  24. References (cont)

More Related